ARRAY BIOPHARMA INC's gross profit margin for the third quarter of its fiscal year 2016 is essentially unchanged when compared to the same period a year ago. Sales and net income fell significantly, underperforming compared to the average company in its industry.
At the same time, stockholders' equity ("net worth") has significantly decreased by 129.51% from the same quarter last year.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY16||Q3 FY15|
|Net Sales ($mil)||43.05||86.61|
|Net Income ($mil)||-22.68||58.31|
|Balance Sheet||Q3 FY16||Q3 FY15|
|Cash & Equiv. ($mil)||0.0||190.07|
|Total Assets ($mil)||196.18||208.45|
|Total Debt ($mil)||112.0||107.99|
|Profitability||Q3 FY16||Q3 FY15|
|Gross Profit Margin||86.42||87.1|
|Return on Assets||-41.06||-2.94|
|Return on Equity||0.0||-12.23|
|Debt||Q3 FY16||Q3 FY15|
|Share Data||Q3 FY16||Q3 FY15|
|Shares outstanding (mil)||143.34||140.43|
|Div / share||0.0||0.0|
|Book value / share||-0.1||0.36|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1729753.0||3170419.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.
|ARRY NM||Peers 189.43||ARRY NA||Peers 35.84|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
ARRY's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures.
Ratio not available.
|ARRY NM||Peers 30.55||ARRY NA||Peers 1.60|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
ARRY's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|ARRY NM||Peers 9.66||ARRY -375.00||Peers -10.77|
Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
ARRY's P/B is negative making this valuation measure meaningless.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, ARRY is expected to significantly trail its peers on the basis of its earnings growth rate.
|ARRY 4.22||Peers 266.68||ARRY -14.83||Peers 45.83|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
ARRY is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
ARRY significantly trails its peers on the basis of sales growth
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.